Astellas Pharma is promoting company-wide initiatives and setting indicators to improve sustainability. The social impact for FY2024 is reported as Product Impact of USD 27,861 million, Human Capital Impact of USD 528.5 million, and Environmental Impact of -USD 32.7 million.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4503","jir_company_name":"Astellas Pharma Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-26","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4503-20260226-01.pdf","jir_short_summary":"Astellas Pharma is promoting company-wide initiatives and setting indicators to improve sustainability. The social impact for FY2024 is reported as Product Impact of USD 27,861 million, Human Capital Impact of USD 528.5 million, and Environmental Impact of -USD 32.7 million.","jir_summary":"### Sustainability Initiatives and Corporate Value Enhancement\nAstellas Pharma promotes a sustainability strategy aimed at contributing to society through its core business and enhancing the sustainability of both society and the company. Since fiscal 2021, it has selected material issues and set indicators in fiscal 2023 to implement company-wide initiatives. To enhance corporate value, it strategically advances strengthening the growth foundation, creating innovation, strengthening governance, environmental considerations, and strengthening health systems.\n\n### Calculation and Results of Social Impact\nThe social impact for FY2024 includes a Product Impact of USD 27,861 million (FY2023 +17.2%), Human Capital Impact of USD 528.5 million (+2.0% YoY), Environmental Impact of -USD 32.7 million (+0.9% YoY with a decreasing trend), and Access to Health Impact of USD 9.59 million. While revenue from sales has increased due to efforts to reduce environmental burden, environmental impact has decreased. Visualization of non-financial value enhances confidence in sustainable growth.","jir_financial_highlights":"Product Impact: USD 27,861 million (FY2023 +17.2%)\nHuman Capital Impact: USD 528.5 million (FY2023 +2.0%)\nEnvironmental Impact: -USD 32.7 million (FY2023 +0.9% (Decreasing trend))\nAccess to Health Impact: USD 9.59 million (Unknown)","jir_category":"","jir_hashtags":"#AstellasPharma, #Sustainability, #ESG","jir_key_figures":"FY2024 Product Impact: USD 27,861 million (FY2023 +17.2%)\nFY2024 Human Capital Impact: USD 528.5 million (FY2023 +2.0%)\nFY2024 Environmental Impact: -USD 32.7 million (Approximately 19% decrease compared to FY2018)","jir_meta_title":"Astellas Pharma's Sustainability Strategy and FY2024 Social Impact Report","jir_meta_description":"Astellas Pharma set indicators to enhance sustainability and achieved FY2024 results of Product Impact USD 27,861 million, Human Capital Impact USD 528.5 million, and Environmental Impact of -USD 32.7 million.","jir_og_title":"Astellas Pharma Sustainability Meeting 2025","jir_og_description":"Report on Astellas Pharma\u2019s sustainability initiatives and FY2024 social impact, detailing product, human capital, and environmental impacts.","jir_og_image_url":"\/assets\/og\/company-esg_sustainability.jpg","jir_chart_data_collection":"[]","ir_related_company":6911,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"esg_sustainability","footnotes":""},"sector":[],"importance":[],"class_list":["post-31294","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n